PMID: 2495049Feb 18, 1989Paper

Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group

BMJ : British Medical Journal

Abstract

To determine whether ketanserin, an antagonist at the serotonin receptor, prevents important vascular events such as death, myocardial infarction, major stroke, and amputation of a leg in patients with claudication. Double blind, randomised, placebo controlled trial after a single blind run in period of placebo treatment for one month. One hundred and forty seven outpatient clinics in 14 countries. Total of 3899 patients over 40 years old who had had documented intermittent claudication for at least two months and in whom the ratio of systolic blood pressure in the ankle to that in the arm was less than or equal to 0.85 in both arteries of at least one foot. After the one month placebo run in period patients were randomly allocated to take 20 mg ketanserin three times daily for the first month and 40 mg three times daily thereafter or to take the same number of placebo tablets. Five months after the onset of the trial, on the recommendation of the ethical and safety committee, four patients stopped taking ketanserin and two stopped taking placebo because they had a corrected QT interval greater than 500 ms. Four months later the committee recommended that all patients taking diuretics should stop receiving trial treatment (167 ...Continue Reading

References

Sep 1, 1987·The American Journal of Cardiology·J D CohenK A Daniels
Apr 1, 1988·JAMA : the Journal of the American Medical Association·J WikstrandG Berglund
Nov 1, 1986·American Heart Journal·J D Coffman
Feb 1, 1984·British Heart Journal·J K McKibbinI W Obel
Sep 1, 1984·British Heart Journal·M J AntonaccioL F Soyka

❮ Previous
Next ❯

Citations

Jun 1, 1995·Journal of Clinical Pharmacology·W H FrishmanB Shareef
Jan 1, 1997·Cardiovascular Drugs and Therapy·J R Hampton
Jan 1, 1990·Cardiovascular Drugs and Therapy·A E Doyle
Jan 1, 1990·Cardiovascular Drugs and Therapy·C MarksM VandenBurg
Jan 1, 1990·Cardiovascular Drugs and Therapy·S T McCarthyS E Gould
Jan 1, 1990·Cardiovascular Drugs and Therapy·K KorliparaA Chandler
Jan 1, 1990·Cardiovascular Drugs and Therapy·J I Robertson
Dec 1, 1991·Cardiovascular Drugs and Therapy·J R Hampton
Oct 1, 1989·Cardiovascular Drugs and Therapy·J R Hampton
May 1, 1994·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·R CirilloM Prosdocimi
Mar 10, 2001·European Journal of Pharmacology·S E O'ConnorP Janiak
Jan 6, 2000·Lancet·D L DeMetsD G Julian
Mar 27, 2001·European Journal of Obstetrics, Gynecology, and Reproductive Biology·A C BolteG A Dekker
Feb 15, 2001·Progress in Retinal and Eye Research·I O HaefligerT F Lüscher
May 24, 2001·The New England Journal of Medicine·W R Hiatt
Jan 1, 1990·British Journal of Clinical Pharmacology·P A van ZwietenP van Brummelen
Jan 1, 1990·European Journal of Clinical Pharmacology·P A van Zwieten
Dec 1, 1990·Cardiovascular Drugs and Therapy·P A van ZwietenP van Brummelen
Jul 31, 2007·Expert Opinion on Pharmacotherapy·Daniel A Duprez
May 23, 2000·Annals of Medicine·W H Frishman, P Grewall
Jan 9, 2003·Expert Opinion on Investigational Drugs·Daniel A DuprezAlan T Hirsch
Jan 1, 1989·Clinical and Experimental Hypertension. Part A, Theory and Practice·T C Chalmers, G D Murray
Nov 18, 1998·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·I DawsonJ H van Bockel
May 1, 1996·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·I SmithJ T Powell
Aug 13, 2014·Asian Cardiovascular & Thoracic Annals·Sefa Senol, Mehmet Ugur Es
Aug 3, 1999·Circulation·K VikenesJ E Nordrehaug
Oct 1, 1992·British Heart Journal·J R Hampton, A M Skene
Aug 1, 1993·Statistics in Medicine·S J Pocock
Jul 25, 1992·BMJ : British Medical Journal·S J Pocock
Jun 3, 2008·British Journal of Haematology·Simon F De MeyerHans Deckmyn
Aug 1, 1992·The Journal of International Medical Research·M CatalanoA Libretti
Sep 1, 1991·La Revue de médecine interne·P AmbrosiR Luccioni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.